Zhejiang Shapuaisi Pharmaceutical Co Ltd (SHG:603168) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168)
Zhejiang Shapuaisi Pharmaceutical Co Ltd (SHG:603168) has a market capitalization of $278.66 Million (CN¥1.90 Billion) as of June 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #15274 globally and #4499 in its home market, demonstrating a -6.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Shapuaisi Pharmaceutical Co Ltd's stock price CN¥5.09 by its total outstanding shares 374126505 (374.13 Million). Review Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) total liabilities to assess the company's total debt and financial obligations.
Zhejiang Shapuaisi Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Shapuaisi Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.57 Billion to $278.66 Million (-14.77% CAGR).
Zhejiang Shapuaisi Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Shapuaisi Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.76x
Zhejiang Shapuaisi Pharmaceutical Co Ltd's market cap is 0.76 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.57 Billion | $921.67 Million | $176.04 Million | 1.71x | 8.94x |
| 2016 | $1.21 Billion | $978.73 Million | $275.72 Million | 1.24x | 4.40x |
| 2017 | $611.23 Million | $938.88 Million | $146.36 Million | 0.65x | 4.18x |
| 2018 | $372.83 Million | $607.44 Million | -$126.47 Million | 0.61x | N/A |
| 2019 | $472.43 Million | $515.96 Million | $7.86 Million | 0.92x | 60.13x |
| 2020 | $427.30 Million | $358.23 Million | -$179.37 Million | 1.19x | N/A |
| 2021 | $516.69 Million | $629.76 Million | $35.66 Million | 0.82x | 14.49x |
| 2022 | $497.07 Million | $549.54 Million | $44.75 Million | 0.90x | 11.11x |
| 2023 | $734.15 Million | $644.97 Million | $25.41 Million | 1.14x | 28.89x |
| 2024 | $366.80 Million | $483.96 Million | -$123.44 Million | 0.76x | N/A |
Competitor Companies of 603168 by Market Capitalization
Companies near Zhejiang Shapuaisi Pharmaceutical Co Ltd in the global market cap rankings as of June 22, 2026.
Key companies related to Zhejiang Shapuaisi Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Zhejiang Shapuaisi Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Shapuaisi Pharmaceutical Co Ltd's market cap moved from $1.57 Billion to $ 278.66 Million, with a yearly change of -14.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥278.66 Million | -30.84% |
| 2025 | CN¥402.93 Million | +9.85% |
| 2024 | CN¥366.80 Million | -50.04% |
| 2023 | CN¥734.15 Million | +47.70% |
| 2022 | CN¥497.07 Million | -3.80% |
| 2021 | CN¥516.69 Million | +20.92% |
| 2020 | CN¥427.30 Million | -9.55% |
| 2019 | CN¥472.43 Million | +26.71% |
| 2018 | CN¥372.83 Million | -39.00% |
| 2017 | CN¥611.23 Million | -49.65% |
| 2016 | CN¥1.21 Billion | -22.86% |
| 2015 | CN¥1.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Zhejiang Shapuaisi Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $278.66 Million USD |
| MoneyControl | $278.66 Million USD |
| MarketWatch | $278.66 Million USD |
| marketcap.company | $278.66 Million USD |
| Reuters | $278.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Shapuaisi Pharmaceutical Co Ltd
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. Zhejiang Shapuaisi… Read more